Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

70
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
70
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

111
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
111
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

93
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
93
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

386
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
386
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

72
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
72

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Evolving Concepts of Treatment Targets for Primary Biliary Cholangitis: A Global Perspective.

The American journal of gastroenterology·2026
Same author

Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.

Hepatology communications·2026
Same author

Gaps in Guideline Adherence for Primary Sclerosing Cholangitis in North America-A 5-Year Analysis.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in ELATIVE.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Impact of Alkaline Phosphatase Normalization on Complication-Free Survival in Primary Biliary Cholangitis.

The American journal of gastroenterology·2026
Same author

Nebokitug, an Anti-chemokine (C-C Motif) Ligand 24 Monoclonal Antibody, in Patients With Primary Sclerosing Cholangitis: A Phase 2 Study.

The American journal of gastroenterology·2025

相关实验视频

Updated: Jun 4, 2025

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

15.5K

初级胆道胆管炎:个性化二线疗法

Cynthia Levy1,2, Christopher L Bowlus3

  • 1Schiff Center for Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA.

Hepatology (Baltimore, Md.)
|December 21, 2024
PubMed
概括
此摘要是机器生成的。

主要胆道胆炎 (PBC) 治疗涉及ursodeoxycholic acid,新的药物如obeticholic acid,elafibranor和seladelpar为需要二线治疗的患者提供了更好的结果.

更多相关视频

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
12:36

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

15.5K
Generation and Quantitative Characterization of Functional and Polarized Biliary Epithelial Cysts
09:55

Generation and Quantitative Characterization of Functional and Polarized Biliary Epithelial Cysts

Published on: May 16, 2020

3.8K

相关实验视频

Last Updated: Jun 4, 2025

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

15.5K
Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
12:36

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

15.5K
Generation and Quantitative Characterization of Functional and Polarized Biliary Epithelial Cysts
09:55

Generation and Quantitative Characterization of Functional and Polarized Biliary Epithelial Cysts

Published on: May 16, 2020

3.8K

科学领域:

  • 肝病学 肝病学是一种肝病学.
  • 免疫学 免疫学 免疫学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 主要胆道胆炎 (PBC) 是一种自身免疫性肝脏疾病,主要影响中年妇女的胆道.
  • 乌尔苏多氧胆酸 (UDCA) 是标准的第一线治疗,延迟了进展,但没有缓解症状.
  • 由于对UDCA的反应不足,许多患者需要二线治疗.

研究的目的:

  • 审查影响决定启动二线治疗PBC的患者因素.
  • 讨论基于疗效和耐受性的二线药物的个性化选择.
  • 为了突出PBC治疗超越UDCA的近期进展.

主要方法:

  • 对PBC病理生理学和治疗指南的当前文献的综述.
  • 对PBC中二线药物的临床试验数据的分析.
  • 讨论与治疗选择相关的患者特征.

主要成果:

  • 二线药物,包括obeticholic acid,elafibranor,seladelpar,besafibrate和fenofibrate,在UDCA反应不足的PBC患者中显示出生化改善.
  • 乙酸改善肝脏的生物化学,但可能导致.
  • 像elafibranor和seladelpar这样的PPAR激动剂显示出希望,可能与生化标志物一起改善.

结论:

  • 个性化治疗策略对于优化PBC管理至关重要.
  • 选择二线药物需要仔细考虑个体患者的需求,包括症状负担和潜在的副作用.
  • 新的药物为患有晚期或耐火性PBC的患者提供了改进的治疗选择.